Anavar: The 'Mild' Oral AAS — Educational Reference
Last updated: October 2026
Oxandrolone (Anavar) is an oral anabolic-androgenic steroid. FDA first approved it in 1964 but withdrew approval of brand-name and generic oxandrolone tablets in June 2023, later concluding its benefit-risk profile was unfavorable given safety warnings and no substantial evidence of effectiveness. This educational reference covers its pharmacology, clinical research in weight loss, HIV wasting, and burn recovery, hepatotoxicity risks, and suppression profile for harm reduction.
withdrawn June 2023
daily, in 2–4 divided doses
10.4 h younger, 13.3 h elderly
How Oxandrolone Works
Oxandrolone is a synthetic DHT derivative with a unique modification: an oxygen atom replaces carbon-2 in the A-ring; it is described as strongly anabolic with reduced androgenic activity, though the label says the two were never fully separated. The C-17α methyl group enables oral bioavailability.
Like other anabolic steroids, oxandrolone acts through the androgen receptor. Trial investigators have described it as having potent anabolic activity with minimal androgenic effects (PMID 8970686), but the former FDA label states that complete dissociation of anabolic and androgenic effects has not been achieved. Its FDA approval was withdrawn in 2023.
Oxandrolone is a non-aromatizable androgen (PMID 2401714), so it does not convert to estrogen and avoids estrogen-driven side effects. That does not make fluid or breast effects impossible: the former FDA label still listed edema, electrolyte retention, and gynecomastia among adverse reactions associated with anabolic steroids. Androgenic effects like DHT-related hair loss also remain possible.
Despite its mild reputation, oxandrolone is 17α-alkylated. Transaminase (ALT/AST) increases were significant in a controlled HIV trial (PMID 16540931), and the former FDA label warned of peliosis hepatis, liver cell tumors (sometimes fatal), and cholestatic hepatitis. "Mild" refers to its androgenic and estrogenic profile — not liver safety. The label described 2–4 week courses, repeated intermittently, with periodic liver function tests.
Oxandrolone suppresses the hypothalamic-pituitary-testicular axis. In a 262-man RCT at 20–80mg/day it significantly lowered LH, FSH, and total and free testosterone (PMID 16540931). The label notes anabolic steroids inhibit pituitary LH and, at large doses, may suppress spermatogenesis. No controlled data set a recovery timeline — confirm recovery with bloodwork.
What Clinical Literature Shows
Data from published clinical trials on oxandrolone in HIV-associated weight loss, burns, and older men. HIV wasting, burns, and Turner syndrome were research uses, not labeled FDA indications, and FDA withdrew the drug's approval in 2023.
Side Effects & Risks
Key Takeaways
- FDA approval (1964) was withdrawn in June 2023; labeled uses were weight regain after surgery, infection, or trauma, corticosteroid-related catabolism, and osteoporosis bone pain
- Described as potently anabolic with minimal androgenic effects, though the label says the two are never fully separated
- Does not aromatize to estrogen — yet edema and gynecomastia were still listed label adverse reactions
- Mean half-life about 10 hours in younger adults and 13 hours in the elderly (FDA label)
- Still hepatotoxic — 17α-alkylated; the label warned of peliosis hepatis and liver tumors
- Can virilize women — the label warns some changes are irreversible even after stopping
- Suppresses LH, FSH, and testosterone in controlled trials
- Labeled courses ran 2–4 weeks, repeated intermittently, with periodic liver tests
- Long-term cardiovascular outcomes in recreational bodybuilding doses poorly documented
- Optimal TUDCA/NAC dosing for oxandrolone-specific hepatoprotection not established by RCT
- Individual variation in 17α-methylation metabolism creates unpredictable hepatotoxicity
- Exact virilization threshold dose in women — irreversible effects possible
- "Mild" label creates dangerous underestimation of real hepatic and lipid risks
🛒 Liver Support & Monitoring
The former FDA label called for periodic liver function tests and lipid panels. Don't skip bloodwork — "mild" doesn't mean liver-safe.
Related Resources
Want the Complete Protocol Guide?
Dosing schedules, interaction warnings, and cycle protocols for 50+ compounds — all in one place.
Get the Guide — $19 (normally $29) →
New to peptides? Start with the $19 Buyer’s Playbook →
This page is for educational and harm reduction purposes only. It is not medical advice. Oxandrolone (Anavar) is a Schedule III controlled substance in the United States under the Anabolic Steroid Control Act of 1990. Possession, distribution, or use without a valid prescription is illegal and carries serious legal penalties. Anabolic steroids carry significant health risks including liver damage, cardiovascular disease, and hormonal disruption. Always consult a qualified physician before making any decisions regarding hormone use. HighPeptides does not endorse or encourage the use of controlled substances.
Get the Free 2026 Peptide Protocol Stack
Twelve compounds across four pillars — metabolic, tissue repair, longevity, cognitive. Citations included, formatted to print. Sent straight to your inbox.